Dupuytren's disease - results of the RIDD trial 

In what could be a breakthrough for patients with Dupuytren's disease, the RIDD trial showed that Injection of the anti-TNF drug adalimumab into Dupuytren’s disease nodules is effective in reducing nodule hardness and nodule size.